Trial Profile
A Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of Repeated Intravenous Doses of BTT-1023 in Patients With Rheumatoid Arthritis - a Double-Blind Randomized Placebo-Controlled Sequential Group Trial.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Timolumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Biotie Therapies Corp.
- 21 Jan 2010 Status changed from active, no longer recruiting to completed.
- 19 Jan 2010 Status changed from active, no longer recruiting to completed, based on information published in a media release from Biotie.
- 04 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.